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In idiopathic pulmonary arterial hypertension, exposure to indirect measures of traffic-related air 
pollution was associated with hemodynamic severity and ERS/ESC risk score at baseline, whereas 




While traffic and air pollution exposure is associated with increased mortality in numerous diseases, 
its association with disease severity and outcomes in pulmonary arterial hypertension (PAH) remains 
unknown. 
Exposure to particulate matter гヲくヵ´ﾏ3 (PM2.5), nitrogen dioxide (NO2) and indirect measures of 
traffic-related air pollution (distance to main road and length of roads within buffer zones 
surrounding residential addresses) were estimated for 301 patients with idiopathic/heritable PAH 
recruited in the UK PAH national Cohort study. Associations with transplant-free survival and 
pulmonary hemodynamic severity at baseline were assessed, adjusting for confounding variables 
defined a priori.  
Higher estimated exposure to PM2.5 was associated with higher risk of death or lung transplant 
(Unadjusted hazard ratio (HR) 2.68;95%CI 1.11-6.47 per 3´g/m3,p=0.028). This association remained 
similar when adjusted for potential confounding variables (HR 4.38;95%CI 1.44-13.36 per 
3´g/m3,p=0.009). No associations were found between NO2 exposure or other traffic pollution 
indicators and transplant-free survival. Conversely, indirect measures of exposure to traffic-related 
air pollution within the 500-1000m buffer zones correlated with the ERS/ESC risk categories as well 
as pulmonary hemodynamics at baseline. This association was strongest for pulmonary vascular 
resistance.  
In idiopathic/heritable PAH, indirect measures of exposure to traffic-related air pollution were 
associated with disease severity at baseline, whereas higher PM2.5 exposure may independently 
predict shorter transplant-free survival.   
Keywords: pulmonary hypertension, pulmonary arterial hypertension, air pollution, traffic pollution, 




Air pollution is an important contributor to premature deaths with over 7 million deaths per year 
being attributable to traffic and air pollution exposure worldwide [1]. Enhanced exposure to multiple 
air pollutants, including nitrogen dioxide (NO2), sulfur dioxide (SO2) and fine particulate matter with 
an aerodynamic diameter of <2.5 m (PM2.5) have been described as independent risk factors for 
mortality and hospitalisations in the general population [2, 3]. This has also been observed in specific 
chronic health conditions, including chronic obstructive pulmonary disease [4, 5], pulmonary fibrosis 
[6-9] and cardiovascular diseases [10]. Of all of these pollutants, PM2.5 has the greatest effect on 
human health [2, 11]. Over two thirds of premature deaths attributable to ambient PM2.5 air 
pollution are due to cardiovascular disease [3, 12]. Both acute and chronic exposure to PM2.5 
increases the risk of cardiovascular death [2, 13], although long-term effects of PM2.5 appear to have 
a greater impact on cardiovascular mortality [10, 14]. Amongst cardiovascular events, the 
occurrence of heart failure exhibited the strongest association with PM2.5 exposure [13, 15].  
Limited data are available regarding the association between air pollution and outcomes in 
pulmonary arterial hypertension (PAH), a disease characterised by vasoconstriction and obliterative 
changes in the small pulmonary arteries, leading to right ventricular (RV) failure and death. As for 
other respiratory diseases, the close relationship between the pulmonary vascular bed and alveolar 
ventilation makes it highly plausible that air pollution directly affects the pulmonary circulation. Not 
surprisingly, preclinical studies have suggested that prolonged exposure to particulate and soluble 
antigens can induce changes in pulmonary arteries [16] and that diesel exhaust exposure induces 
pulmonary hypertension in mice [17]. Imaging studies also found an association between air 
pollution and changes in RV mass and function within the general population [18, 19]. Since RV 
function has been repeatedly shown to represent a major determinant of prognosis in PAH [20], we 
hypothesized that exposure to air pollution is associated with disease severity and outcomes in PAH.  
 
METHODS 
Study population and socioeconomic status 
Patients were recruited prospectively from the United Kingdom (UK) national Cohort study of 
idiopathic and heritable PAH (www.ipahcohort.com), a multicentre prospective study investigating 
the genetic and environmental causes of PAH (see online supplement for details). Consecutive 
patients with idiopathic and heritable PAH were then invited to complete a comprehensive 
epidemiological questionnaire. They were considered eligible if they maintained the same address 
since diagnosis to minimize the risk of exposure misclassification. Potential confounding due to 
socioeconomic status [21] was addressed by assigning an area-level deprivation to their residential 
address for each patient using time-weighted Townsend deprivation quantiles that are available for 
the UK (https://data.mendeley.com/datasets/389scnndjy/1). Moreover, household income data 
were collected via questionnaire, taking into account household size and composition [22]. We also 
accounted for the level of education collected via the epidemiological questionnaire using nine 
International Standard Classification of Education (ISCED) codes that were collapsed to three 
categories (Primary & Lower Secondary, Upper & Post-Secondary and Tertiary) as a measure of 
socioeconomic status. The Regional Ethics Committee approved this study (REC 13/EE/0203) and 
participants provided written informed consent. Area-level and individual-level deprivation 
indicators were used in all statistical analyses, given the recognised confounding between 
deprivation and exposure to air pollution.  
 
Air pollution exposure measures 
Each participantげゲ residential address was assigned a geographic coordinate using QGIS v2.18 
software (https://qgis.org) in conjunction with the UK geocoding database 
(http://dx.doi.org/10.5257/census/geoconvert-1). The geocoded ヮ;デｷWﾐデゲげ residential addresses 
were linked to average levels of PM2.5 and NO2 annual means using existing 2010 UK-wide maps 
(Figure S1), which were based on routine air pollution monitoring data incorporating satellite-
 
derived and chemical transport model estimates plus road and land use data [23]. We assessed 
associations between mortality as well as disease severity ┘ｷデｴ W┝ヮﾗゲ┌ヴW デﾗ ｷﾐIヴW;ゲWゲ ﾗa ン ´ｪっﾏ3 for 
PM2.5 ;ﾐS ヱヰ ´ｪっﾏ3 for NO2 that correspond to observed interquartile ranges rounded to the nearest 
integer. We also acquired air pollution monitoring data from the Automatic Urban and Rural 
Network for the period 01/01/1999に31/12/2017. We obtained hourly data for PM2.5 and NO2 from 
59 and 73 monitors, respectively, and computed daily averages (Figure S2). To link monitoring data 
to each residential postal code, we identified the nearest monitoring site within 50 km of the postal 
code (based on centroid point) and assigned air pollutant measurements to that postal code. If there 
were no monitoring sites within the 50 km zones, we treated the monitored exposure level as 
missing and excluded that postal code from the analysis. We estimated cumulative air pollution 
concentrations at lags of 0, 3, 7 and 14 days to assess short-term effects of air pollution 
concentrations on pulmonary haemodynamics at the time of diagnosis. Finally, residential proximity 
to motorways and A-roads, which form the major road network in the country, as well as total 
length of roads within different buffers (100, 200, 500 and 1000 meters) ;ヴﾗ┌ﾐS ヮ;デｷWﾐデゲげ ｴﾗﾏW 
addresses were estimated as indicators of traffic related air pollution (Figure S3). 
 
Health outcome measures 
The primary outcome measure was transplant-free survival from time of diagnosis. We also assessed 
whether markers of air pollution correlated with disease severity, using baseline pulmonary 
hemodynamic data, namely pulmonary vascular resistance (PVR), mean pulmonary arterial pressure 
(PAP), cardiac index (CI) and right atrial pressure (RAP). We finally assessed whether markers of air 
pollution are associated with the abbreviated 2015 European Society of Cardiology (ESC)/European 
Respiratory Society (ERS) risk stratification strategy, as previously described (Table S1)  [24]. 
 
Statistical analysis 
Associations of air pollution exposure estimates with risk of death or lung transplantation were 
assessed based on hazard ratios (HR) from Cox proportional hazards regression models. In the crude 
model, we stratified by centre, allowing baseline hazards to be unique for each stratum. In the 
primary adjustment model, we further adjusted for age, sex and World Health Organisation (WHO) 
functional class. We fitted a further-adjusted model accounting for additional confounders including 
area and individual-level deprivation, smoking status at diagnosis (current/former/never), season, 
body mass index, bone morphogenetic protein receptor type II (BMPR2) gene mutation and whether 
the patient was incident (diagnosed for <6 months at study entry) or prevalent. The latter 
adjustment controlled for any potential survivor bias introduced by the inclusion of prevalent cases 
in the survival analysis. The covariates were chosen a priori on the basis of potential confounding 
when assessing health effects of air pollution exposures in PAH. The same covariates were also used 
in models for disease severity associations.  
In survival analysis, we added the ERS/ESC risk category and emphysema as covariates, due to their 
known effect on mortality as well as data completeness. Given the relatively small number of 
deaths, we consider the crude and primary adjustment models as reasonable, but caution over 
interpretation of results from the further adjusted model due to overfitting. To minimize the scope 
for potential survivor bias due to inclusion of prevalent patients, Cox proportional hazards regression 
models and survival curves were fitted allowing for left truncation arising from the interval between 
diagnosis and enrolment. Prevalent patients were only included in the risk set from the time of study 
entry and were excluded if they entered the study more than 10 years after diagnosis. 
Linear mixed-effects regression was used to characterise the relationships between air pollution 
measures and pulmonary haemodynamics, grouping observations by centre. As the haemodynamic 
outcome variables were natural log-デヴ;ﾐゲaﾗヴﾏWSが デｴW Wゲデｷﾏ;デWS ヴWｪヴWゲゲｷﾗﾐ IﾗWaaｷIｷWﾐデゲ ふさɴ-
IﾗWaaｷIｷWﾐデゲざぶ ┘WヴW W┝ヮﾗﾐWﾐデｷ;デWS ふｷくWく ݁ߚ) and more naturally interpreted as the expected relative 
 
(or percentage) change in outcome. The interpretation of results with outcomes modelled on the 
logarithmic scale is presented in the online supplement. The relationship between air pollution 
measures and ERS/ESC clinical risk prediction tool (low, intermediate or high-risk categories) was 
similarly evaluated, using multinomial logistic regression. We excluded the functional class variable 
from the further-adjusted model, as it is required for the estimation of ERS/ESC risk score at 
baseline.  
In order to make the survival analysis models (crude, primary and further-adjusted) as comparable 
as possible, we used a complete-case dataset (N=286) with no missing data of all the variables used 
for adjustment. We further limited this dataset to a complete-case dataset for haemodynamic 
variables (N=243) for the disease severity analyses. It was considered unreasonable to conduct 
multiple imputation analysis as haemodynamics were the health outcomes. The variables of the 
さﾐW;ヴWゲデ ﾏﾗﾐｷデﾗヴざ W┝ヮﾗゲ┌ヴW ;ﾐ;ﾉ┞ゲｷゲ ┘WヴW W┝WﾏヮデWd from the complete-case datasets, due to large 
ﾐ┌ﾏHWヴゲ ﾗa ﾏｷゲゲｷﾐｪ ヴWIﾗヴSゲ ﾗﾐ デｴW ;ｷヴ ヮﾗﾉﾉ┌デｷﾗﾐ デｷﾏW ゲWヴｷWゲ ;ヴﾗ┌ﾐS デｴW ヮ;デｷWﾐデゲげ Sｷ;ｪﾐﾗゲｷゲ S;デWゲく 
When assessing associations with length of road, we accounted for the absence of a major road 
within the 500-1000m buffer zones around residences by adding a binary (yes/no) variable on the 
respective models. We did not model the effect of length of road within the 100-200m buffer zones 
as only few participants had a major road within these zones. The traffic exposure indicators 
were log transformed. Therefore log-log regression models were fitted when assessing their 
association to haemodynamic measures. The exponentiated association estimates were 
naturally interpreted as expected relative (or percentage) change in haemodynamic outcome for a 
percent increase in the traffic exposure indicators. Further information on the interpretation of 
these models is presented in the online supplement. Methods used to assess the validity of the 
models and the robustness of the final results are also presented in the online supplement. Data 
were presented as means ± standard deviation or median [interquartile range] according to data 
distribution. Analyses were performed using R software, version 3.4.1 (R Project for Statistical 
 
Computing), and STATA software, version 14 (StataCorp, College Station, TX, USA). P values <0.05 




Of 537 patients recruited in the UK PAH Cohort from Jan 2014 to February 2018, 406 (76%) patients 
were offered and accepted to complete the questionnaire. One hundred of them were excluded as 
they moved since diagnosis, and 5 were excluded as coordinates/addresses were missing, leaving 
301 patients for analysis (Figure 1). These patients were recruited in 7 UK PAH expert centres (Table 
S2). The non-eligible participants were older and more likely to be incident cases (Table S3). 
Characteristics of the study participants are described in Table 1, and were comparable to complete-
case datasets used for modelling (Tables S4). Table 2 provides summaries of ambient and traffic-
related air pollution indicators. 
 
During a mean follow-up of 3.5 years (4.5 years for prevalent cases), 35 (13%) participants died and 
5 (2%) were transplanted, resulting in a 1, 3 and 5-year transplant-free survival estimates of 97%, 
85% and 67% for incident patients, and 100%, 100% and 88% for prevalent patients, respectively. 
The distribution of PM2.5 exposure, among those participants who died compared to those who did 
not, is presented in Figure S4. Exposure to higher PM2.5 annual (2010) mean concentrations was 
associated with higher risk of death or lung transplant (Unadjusted HR (2.68;95%CI 1.11-6.47 per 
3´g/m3,p=0.028) (Table 3). Similar estimates were observed when adjusting for potential 
confounding variables (HR 4.38;95%CI 1.44-13.36 per 3´g/m3,p=0.009). Conversely, no associations 
were found between recent exposure to PM2.5 at the time of baseline catheterization (nearest 
monitoring sites), exposure to NO2 or traffic-related pollution indicators and mortality. However, 
increases in the sum of the length of main roads within the 500m-buffer zone were associated with 
 
higher PAH risk score at baseline, increasing the likelihood of being diagnosed within the ESC/ERS 
high-risk clinical prediction category (Figure 2).  
Baseline hemodynamic severity correlated with distance to main road and the length of road 
surrounding the residential addresses for both the crude (Figure S5) and the further-adjusted (Figure 
3) models. The strongest evidence for this association was found between pulmonary vascular 
resistance and distance to road indicator, with expected relative change of 0.95 (95%CI 0.93-0.98, 
p=0.001) for a 200m increase. Surprisingly, increased exposure to PM2.5 (2010 map) was associated 
with a lower pulmonary vascular resistance (Figure 4). No consistent association was found between 
pulmonary haemodynamics and NO2 (Figure S7-8).  
 
DISCUSSION 
The main findings of this multicentre UK PAH Cohort are that direct and indirect measures of 
exposure to air pollution were associated with more severe disease at baseline and poorer 
transplant-free survival amongst patients with idiopathic and heritable PAH. One exception was that 
increased annual mean PM2.5 concentrations were associated with lower pulmonary vascular 
resistance. While estimated exposure to PM2.5 was independently associated with the risk of death 
or transplantation, traffic air pollution indicators at the time of diagnosis correlated with the 
ESC/ERS risk stratification and baseline hemodynamic severity. These associations should however 
be interpreted with caution given the limited sample size and the indirect measures used as proxy 
for air pollution exposure.  
Increased air pollution exposure has been documented as an independent risk factor for mortality 
and hospitalisations in the general population [2, 3], and in several chronic health conditions [4-9, 
15]. Evidence suggests that these effects are stronger for cardiovascular mortality than for other 
causes of mortality [25, 26]. Moreover, PM2.5 emissions have been consistently found to have more 
detrimental health effects compared to gaseous emissions (e.g. NO2), with cardiovascular events 
 
exhibiting the strongest association with exposure to PM2.5 [13, 15]. Particles generated by diesel 
exhaust are considered particularly toxic since they carry a much larger fraction of toxic compounds 
[10, 27]. Particulate matter is a mixture of solid particles and liquid droplets suspended in the air. 
Contrary to larger particles, PM2.5 have a diameter that enables particles to penetrate deep into the 
lungs and permeate the alveolar-capillary epithelium [25]. The size of particles is thus directly linked 
to their impact to influence human health. Numerous biological mechanisms have been 
hypothesized to explain the association between PM2.5 exposure and cardiovascular diseases. These 
include the possible direct actions of pollutants reaching the lung and the systemic circulation 
contributing to oxidative stress, autonomic imbalance [10, 14], epigenetic dysregulation [28], 
immunomodulation [29] and vascular inflammation [30].  
In the Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air) long-term ambient PM
2.5 
concentrations were shown to be associated with the progression of intimaにmedia thickness on 
ultrasound examination [31] and that ambient air pollution was associated with a greater peripheral 
total pulmonary vascular volume [32]. Interestingly, experimental studies have documented that 
prolonged exposure to particulate and soluble antigens induces changes in pulmonary arteries [16] 
and that diesel exhaust exposure induces pulmonary hypertension in mice [17]. Moreover, an 
echocardiographic study on 81 children living in Mexico also found that outdoor exposure levels of 
PM2.5 were associated with increased pulmonary arterial pressure and with elevated plasma 
endothelin-1 levels [33], while a chamber study on 18 healthy volunteers showed that diesel exhaust 
exposure increases pulmonary vascular resistance at high cardiac output [34]. In view of the small 
numbers of subjects involved in these studies and the limited preclinical experiments on the 
pulmonary circulation physiology in response to pollutants exposure, the mechanisms underlying 
the association between indirect measures of air traffic pollution and hemodynamic severity at 
baseline in the present study remain elusive. Nonetheless, we can speculate that air pollution could 
contribute to enhanced inflammation, oxidative stress, and endothelial dysfunction that have been 
involved in PAH development and progression.  
 
Contrary to the scant evidence on the association between pulmonary vascular dysfunction and air 
pollution in humans, multiple studies confirmed the association between air pollution exposure and 
heart structure and function. The Multi-Ethnic Study of Atherosclerosis (MESA) confirmed that 
people living in proximity to roadways had greater left ventricular mass [35]. More recently, the 
MESA study also confirmed that exposure to higher concentrations of NO2[36], PM2.5 [37] and 
PM2.5-10 [19] were associated with greater RV mass and RV end-diastolic volume. The association 
between chronic past exposure to traffic-related pollutants and RV and left ventricular mass and 
function were also recently replicated within the UK Biobank Population Imaging Study [18]. Even 
acute increases in PM2.5 exposure were recently shown to induce endothelial dysfunction and 
influence cardiac function [38]. Since the prognosis of PAH is mostly influenced by the consequences 
of the increased afterload on the right heart function, the present association between air pollution 
exposure and PAH outcomes is therefore not unexpected.  
To the best of our knowledge, this is the first study that aimed at investigating the association 
between traffic-related and air pollution exposure and hemodynamic severity and outcomes in PAH. 
We found strong evidence for the association between pulmonary vascular resistance and distance 
to the nearest main road. Importantly, despite being exposed at PM2.5 concentrations below current 
air quality standards, PM2.5 exposure was associated with increases in the relative risk of mortality. 
Moreover, this association was robust using different model specifications. Whether this finding is 
related to influences of pollutant exposure on RV function, PAH progression, comorbidities or a 
coincidental finding remains to be investigated. It is noteworthy that the magnitude of this 
association was higher than reported in most observational studies from the general population in 
which relative increases in mortality were most commonly in the range of 4-ヱヵХ ヮWヴ ヱヰ´g/m3 of 
PM2.5 concentrations [2, 3]. Subgroups of the general population can be particularly susceptible 
though to air pollution. In a group of postmenopausal women a 76% increase in the risk of death 
aヴﾗﾏ I;ヴSｷﾗ┗;ゲI┌ﾉ;ヴ SｷゲW;ゲW ┘;ゲ ﾗHゲWヴ┗WS ヮWヴ ヱヰ´ｪっﾏ3 of PM2.5 concentrations [39]. Although the 
ヮヴWゲWﾐデ ゲデ┌S┞げゲ Wゲデｷﾏ;デW ┘;ゲ ｷﾏヮヴWIｷゲWが ┘ｷデｴ ┘ｷSW IﾗﾐaｷSWﾐIW ｷﾐデWヴ┗;ﾉが ｷデ remains nonetheless 
 
consistent with the increased risk of death observed in more vulnerable populations [39-41] as with 
disease-specific mortality [3]. The present results are observed for air pollution levels that meet the 
current air quality standards, which is also the case with other studies in USA and Europe [2, 42]. 
These observations thus support current efforts to improve outdoor air quality and meet the WHO 
reference level for the PM2.5 annual mean concentrations (10 µg/m
3). Intriguingly, previous studies 
suggested that air pollution exposure correlates not only with pulmonary fibrosis severity, but also 
its incidence [9]. While low disease awareness was proposed to explain the higher prevalence of PAH 
in urban regions of France in previous registry data [43], the impact of air pollution cannot be fully 
excluded.  
The present study has several limitations that should be acknowledged. Since evidence suggests that 
mean PM2.5 and NO2 concentrations minimally fluctuate over the years [15], we estimated individual 
exposure to air pollution using the 2010 annual average air pollution maps of ambient PM2.5 and NO2 
concentrations. WW ;ﾉゲﾗ ﾉｷﾐﾆWS W;Iｴ ゲデ┌S┞ ヮ;ヴデｷIｷヮ;ﾐデげゲ ヴWゲｷSWﾐIW デﾗ デｴW ﾉﾗI;デｷﾗﾐ ﾗa デｴW ﾏﾗﾐｷデﾗヴｷﾐｪ 
stations. However, the use of the nearest monitor represents a coarse exposure approach as it does 
not account for spatial heterogeneity due to land use (i.e. roads) or prevailing winds. Thus, 50km can 
capture large rural areas as well as urban areas. Moreover, people who live in industrialized 
countries spend around 90% of their time indoors [44]. Similarly, even if PAH patients are expected 
to spend more time at home than the general population, many people may spend much of their 
time at their workplace, which may be far from their home. In addition, smoking and individual level 
deprivation data only partly captured indoor air quality. Thus, available maps are likely to have led to 
exposure misclassification for many patients of the present cohort. Intriguingly, enhanced 
PM2.5 exposure using 2010 air pollution maps was associated with poorer survival but lower 
pulmonary vascular resistance at baseline. The mechanisms underlying these associations remain 
elusive. It is noteworthy, however, that such discrepancy between specific pollutant exposures and 
outcomes has been repeatedly observed in other conditions, including chronic obstructive 
pulmonary disease [4, 5] and pulmonary fibrosis [7-9]. Additionally, in order to minimize exposure 
 
misclassification, a significant proportion of patients were ineligible as they did not maintain the 
same address since diagnosis. Since moving may not occur randomly, this may have led to selection 
bias, questioning the external validity of our findings. Moreover, the traffic-related air pollutant 
exposure has been associated with outcomes in small cohorts of patients with specific 
cardiorespiratory diseases [7, 8]. However, the present cohort had a smaller sample size than most 
observational studies evaluating the association between traffic road or air pollutant exposure and 
outcomes [2, 42]. Whether the observed associations result from sampling error or reflect the 
vulnerable nature of patients with PAH remains to be determined. The potential for a false positive 
finding also cannot be excluded, since multiple comparisons increase the possibility for type 1 error 
in statistical analyses. Finally, as PM2.5 is a heterogeneous mixture of solid and liquid particles 
emitted from a variety of sources and traffic-related air pollution indicators are indirect measures of 
air pollution, the available data precluded the estimation of the specific constituents and sources of 
the particles. Given these limitations, the current data should be interpreted with caution until 
larger studies are available.  
In conclusion, traffic-related air pollution and PM2.5 exposure may be associated with disease 
severity and outcomes in PAH. However, our findings require validation and replication in a larger 
cohort to increase confidence in the reliability of these estimates.  The present study thus 
encourages further investigations on air pollution exposure as a potentially removable risk factor 
influencing PAH incidence, severity and outcomes.   
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TABLE 1. CHARACTERISTICS OF THE STUDY PARTICIPANTS AT DIAGNOSIS 
 
N=301 
Age at Diagnosis, years 51 ± 15 
Female sex 199 (66) 
PAH subgroup  
Idiopathic 261 (87) 
Heritable 40 (13) 
WHO functional class*  
I-II 44 (15) 
III 219 (73) 
IV 38 (13) 
Body Mass Index (BMI),  kg/m2 30 ± 7 
Presence of emphysema on CT scan* 7 (2) 
Pulmonary hemodynamics   
Right Atrial Pressure (RAP), mmHg 9 [7] 
Mean pulmonary arterial pressure (PAP), mmHg 53 [18] 
Cardiac Index (CI), L/min per m² 2 [1] 
Cardiac Output (CO), L/min  4 [2] 
Pulmonary Vascular Resistance (PVR), Wood units 11 [8] 
Pulmonary capillary wedge pressure (PCWP), mmHg 9 ± 3 
Mixed venous oxygen saturation (SvO2), % 64 ± 8 
Six-minute walk distance (SMWT), meters 310 [203] 
Pulmonary function tests  
Forced expiratory volume in 1 sec (FEV1), 
%predicted 
84 ± 19 
Transfer coefficient (KCO), %predicted  74 ± 24 
Area-level Deprivation  
q1 (most deprived) 95 (32) 
q2 68 (23) 
q3 61 (21) 
q4 52 (18) 
q5  19 (6) 
q6 missing category 6 (2) 
Household Income  
q1 41 (14) 
q2 40 (13) 
q3 40 (13) 
q4 50 (17) 
q5 (most deprived) 28 (9) 
q6 missing category 102 (34) 
Education  
Primary and Low-Secondary  62 (21) 
Upper and Post-Secondary 124 (41) 
Tertiary 90 (30) 
Missing category 25 (8) 
 
Smoking at diagnosis, n (%)  
Current smoker 22 (7) 
Former smoker 92 (31) 
Never smoker 46 (15) 
Missing category 141 (47) 
Ethnicity  
White 271 (90) 
Asian 18 (6) 
Other *** 12 (4) 
 
 
Data are presented as mean±standard deviation, n(%) or median [interquartile range]. 
* The percentages may not add up to 100% due to rounding. 
** The presence of emphysema was based on baseline chest computed tomography at the 
time of diagnosis. 
ゅゅゅ TｴW I;デWｪﾗヴ┞ さOデｴWヴざ ｷﾐIﾉ┌SWゲぎ Black, Mixed and Prefer not to answer. 
ゆD;デ; ┘WヴW IﾗﾏヮﾉWデW aﾗヴ ;ﾉﾉ ┗;ヴｷ;HﾉWゲ W┝IWヮデ ┘ｴWヴW ｷﾐSｷI;デWS H┞ ; ﾏｷゲゲｷﾐｪ I;デWｪﾗヴ┞ ;ﾐS 
further missing data on the continuous variables: BMI 9; RAP, CI 16; PAP 5; CO 10; PVR, 
PCWP 35; SvO2 27; SMWT 92; FEV1 23; and KCO 46. 
 
PAH: pulmonary arterial hypertension; WHO: World Health Organization. 
 
TABLE 2. SUMMARY OF AIR POLLUTION INDICATORS 
Traffic-related air pollution     
 
Distance to road (km) 0.4 [0.5] 
Road length (km) - within 1km buffer zone 2.1 [2.1] 
Road length (km) - within 500m buffer zone 0.8 [1] 
Ambient Air Pollution 
  
Mean annual concentrations for PM2.5 and NO2 
 P;ヴデｷI┌ﾉ;デW ﾏ;デデWヴ ヲくヵが ´ｪっﾏ3 13.7 [2.8] 
NｷデヴﾗｪWﾐ Dｷﾗ┝ｷSWが ´ｪっﾏ3 26 [10.1] 
Nearest  monitor  (<50km) approach for PM2.5 and NO2 at the time of baseline 
right heart catheterization   
P;ヴデｷI┌ﾉ;デW ﾏ;デデWヴ ヲくヵが ´ｪっﾏ3 
 
Lag 0 days * 9.4 [7.9] 
Lag 3 days * 9.3 [7.5] 
Lag 7 days * 10.2 [7.1] 
Lag 14 days * 10.6 [8] 
NｷデヴﾗｪWﾐ Dｷﾗ┝ｷSWが ´ｪっﾏ3 
 
Lag 0 days * 29.3 [30.2] 
Lag 3 days * 27.3 [28] 
Lag 7 days * 28.3 [30.2] 
Lag 14 days * 29.2 [27.4] 
 
Data are presented as median [interquartile range]. 





TABLE 3. COX PROPORTIONAL REGRESSION ANALYSIS FOR THE ASSOCIATION BETWEEN ANNUAL 
(2010) MEAN CONCENTRATIONS OF PARTICULATE MATTER 2.5 EXPOSURE AND RISK OF 
MORTALITY OR TRANSPLANTATION. 
 
Complete Dataset for survival analysis 





Models   
Crude model* 2.68 (1.11-6.47) 0.028 
Primary adjusted model  ** 2.74 (1.06-7.05) 0.037 
Further adjusted model *** 4.38 (1.44-13.36) 0.009 
 
Hazard ratios per 3´g/m3 increase of PM2.5 exposure.  
* Model is stratified by centre. 
** Model adjusted for age, gender, World Health Organisation functional class, stratified by centre. 
*** Model adjusted for centre, age, gender, deprivation, income, education, smoking, 
incident/prevalent, emphysema, European Respiratory Society/European Society of Cardiology risk 
category and bone morphogenetic protein receptor type II gene mutation, stratified by centre. 
 
ゆComplete dataset with no missing data for the variables we adjusted for in the main (survival 
analysis) models (N=286). Due to exclusion criteria related to survival analysis [i.e. prevalent patients 
who were diagnosed more than 10 years before study entry (n=16) and cases who left before the 













FIGURE 2. MULTINOMIAL LOGISTIC REGRESSION ESTIMATING THE ASSOCIATIONS BETWEEN 
PULMONARY ARTERIAL HYPERTENSION RISK PROFILE AND LENGTH OF MAIN ROADS WITHIN THE 
500M-BUFFER ZONE. First three panels (a, b, c) show the expected risk (and 95%CI) of being diagnosed 
in low, intermediate and high-risk profile according to the abbreviated ESC/ERS risk score. An increase 
in length of road was associated with increased probability of having a high-risk score at baseline. Last 
panel (d) summarises the association between the sum of road lengths within the 500m-buffer zone and 




FIGURE 3. MULTIVARIABLE LINEAR REGRESSION ESTIMATING THE ASSOCIATIONS BETWEEN 
PULMONARY HAEMODYNAMICS AND TRAFFIC AIR POLLUTION The fully adjusted models was adjusted 
for: age, sex, functional class, smoking status at diagnosis, season, deprivation, income, education, 
body mass index, prevalent/incident cases, presence of BMPR2 gene mutation and centre. Complete-
case dataset with no missing data for the haemodynamics and the variables we adjusted for (N=243). 
 
Both exposure and haemodynamic variables were log-transformed. Therefore, the relative changes 
represent percentage change of the haemodynamics for a 60% increase in the traffic exposure 
indicators. A 60% increase in the geometric mean of traffic exposure indicators approximates to 200m 
increases for distance to road, 0.6km increases for road length (500m buffer zone) and 1.5km increases 
for road length (1km buffer zone). 
 
N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP mean: 
mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m², RAP: right atrial 




Figure 4. Multivariable Linear Regression Estimating the Associations between Pulmonary 
Haemodynamics and Particulate Matter ≤2.5┢m (PM2.5) concentrations. 
 
The model was fully adjusted for age, sex, functional class, smoking status at diagnosis, season, 
deprivation, income, education, body mass index, prevalent/incident cases, presence of BMPR2 gene 
mutation and centre. 
 
Only haemodynamic variables were log-transformed. Therefore, the relative changes represent 
percentage 
increase in PM2.5 exposure. 
 
N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP mean: 
mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m², RAP: right atrial 





The United Kingdom (UK) National Cohort Study 
The PAH cohort study has recruited adult prevalent and incident patients with idiopathic 
PAH, heritable PAH, and PAH associated with anorexigen exposure, as well as pulmonary 
veno-occlusive disease since January 2014. Heritable PAH was defined on the basis of a 
family history or the finding of a known PAH-causing mutation. All cases were diagnosed 
between January 2000 to February 2018 in seven specialized pulmonary hypertension 
centres in the UK. The diagnostic algorithm, subsequent treatments and follow-ups were 
based on contemporary international guidelines [21]. Baseline clinical and hemodynamic 
characteristics at the time of PAH diagnosis were prospectively entered. Date of diagnosis 
corresponded to that of confirmatory right heart catheterization.  
 
Abbreviated 2015 European Society of Cardiology/European Respiratory Society risk 
stratification strategy 
The abbreviated version of the 2015 European Society of Cardiology (ESC)/European 
Respiratory Society (ERS) risk stratification strategy was used to categorise patients as low, 
intermediate or high risk (Table S1) using the strategy previously proposed [28]. All patients 
had at least three of the six listed variables available. Briefly, the cut-off values proposed in 
the guidelines were graded from 1 (low risk), 2 (intermediate risk) and 3 (high risk). For each 
patient, the sum of all grades was divided by the number of available variables and rounded 
to the next integer to define the risk group. Calculations were made from baseline 
assessments and from follow-up assessments between 3 months and 2 years after the 
initiation of medical therapy for PAH.  
 
 
Table S1. Variables and cut-off values used for risk stratification  
 Low risk Intermediate risk High risk 
WHO FC I-II III IV 
6MWD, m >440 165-440 <165 
BNP, ng·L−1 <50 50-300 >300 
NT-proBNP, ng·L−1 <300 300-1400 >1400 
Right atrial pressure, mmHg  <8 8-14 >14 
Cardiac index, L·min-1·m-2  ≥2.5 2.0-2.4 <2.0 
SvO2, %  >65 60-65 <60 
WHO FC: World Health Organization functional class; BNP: brain natriuretic peptide; NT-
proBNP: N-terminal fragment of pro-brain natriuretic peptide; SvO2: mixed venous oxygen 
saturation.  
 
Interpretation of models with logarithmic transformation 
When a variable was log transformed (i.e. PVR, PAP, CI, RAP), we interpreted the 
exponentiated regression coefficients [exp(beta)] and these values corresponded to changes 
in the ratio of the expected geometric means (instead of the arithmetic means when 
outcomes are not log transformed) of the original outcome variable. For the interpretation of 
the effect of ambient air pollution (PM2.5 and NO2) on haemodynamics (i.e. PVR, PAP, CI, 
RAP), only haemodynamic variables were log-transformed. We therefore assessed the 
expected change in haemodyamics per unit increase [exp(beta*Unit increase)] of air 
pollution concentrations, using a 3-unit and 10-unit increase for PM2.5 and NO2, respectively 
(which corresponded to their interquartile ranges rounded to the nearest integer).  
Conversely, for the assessment of the association between traffic exposure indicators (i.e. 
distance to road, road length surrounding residency) and haemodynamics (i.e. PVR, PAP, 
CI, RAP), both exposure and haemodynamic variables were log-transformed. We interpreted 
the exponentiated regression coefficients that correspond to relative changes, as percentage 
change of the outcome when the traffic exposure indicators increased by x%. In this case, 
we assessed the expected change in haemodyamics for a 60% percent increase in the 
 
geometric mean of traffic indicators (corresponding to meaningful changes on these 
indicators). A 60% increase in the geometric mean of traffic exposure indicators 
approximated to 200m increases for distance to road, 0.6km increases for road length at 
500m buffer zone and 1.5km increases for road length at 1km buffer zone. These values fell 
within the interquartile range of the traffic indicators and are presented in the legend of the 




Table S2. Number of patients recruited per participating centres. 
 
 Centre Counts of 
Patients 
Percentage 
1 Golden Jubilee National Hospital, Glasgow 45 12% 
2 Imperial and Hammersmith Hospital 89 29% 
3 Newcastle Freeman Hospital 17 6% 
4 Royal Papworth Hospital 51 16% 
5 Royal Brompton Hospital 31 12% 
6 Royal Free Hospital 17 6% 
7 Sheffield Teaching Hospital-- Royal Hallamshire Hospital 51 19% 
 Total 301 100% 
 
 












Age at Diagnosis, years 51±15 45±17 <0.001 
Female sex  199(66) 167 (71) 0.292 
PAH type   
0.600 Idiopathic 261 (87) 200 (85) 
Heritable 40 (13) 36 (15) 
WHO functional class   
0.065 
I-II 44 (15) 52 (22) 
III 219 (73) 149 (63) 
IV 38 (13) 35 (15) 
Transfer coefficient (KCO), %predicted 73±24 71±24 0.355 
Pulmonary hemodynamics     
Right Atrial Pressure, mm Hg 9 [7] 8 [6] 0.059 
Mean pulmonary arterial pressure, mm Hg 53 [18] 53 [17] 0.984 
Cardiac Index,/min per m²
 2 [1] 2 [1] 0.287 
Cardiac Output, L/min 4 [2] 4 [2] 0.173 
Pulmonary Vascular Resistance, WU 11 [8] 11 [9] 0.390 
Mixed venous oxygen saturation, % 64 ± 8 65 ± 10 0.263 











    
 
Data are presented as mean±SD, n(%) or median [IQR]. Groups were compared using t-test, Mann-Whitney U Test and chi-squared independence test. 
Definition of abbreviations: BMPR2 = bone morphogenetic protein receptor type II; SD: standard deviation; WHO: world health organization. 
 
TABLE S4. CHARACTERISTICS OF THE STUDY PARTICIPANTS AT DIAGNOSIS: 1) full dataset with missing data for some of the adjusting variables (N=301); 
2) dataset with complete data for adjusting variables used in survival analysis (N=286); 3) dataset with complete haemodynamics and adjusting variables 
used in disease severity analyses (N=243) and 4) dataset with the nearest monitor analyses data available (N=135).   
 
 
Full initial dataset 
(N=301) 
Complete dataset with no 
missing data for the 
variables we adjusted for in 
the main (survival analysis) 
models (N=286), 
Complete Dataset for 
disease severity analyses 
(N=243) 
Complete Dataset, 
limited to cases  with 
ゎﾐW;ヴWゲデ ﾏﾗﾐｷデﾗヴざ ;ｷヴ 
pollution data 
(N=135) 
Age at Diagnosis, years 51 ± 15 51 ± 15 52 ± 16 53 ± 17 
Female sex 199 (66) 189 (66) 161 (66) 88 (65) 
PAH subgroup       
Idiopathic 261 (87) 247 (86) 210 (86) 120 (89) 
Heritable 40 (13) 39 (14) 33 (14) 15 (11) 
WHO functional class*       
I-II 44 (15) 41 (14) 34 (14) 17 (13) 
III 219 (73) 211 (74) 183 (75) 105 (78) 
IV 38 (13) 34 (12) 26 (11) 13 (10) 
Body Mass Index,  kg/m2 30 ± 7 30 ± 7 30 ± 7 30 ± 7 
Presence of emphysema on CT scan* 7 (2) 6 (2) 5 (2) 3 (2) 
Pulmonary hemodynamics        
Right Atrial Pressure, mmHg 9 [7] 8 [7] 8 [6] 8 [6] 
Mean pulmonary arterial pressure, mmHg 53 [18] 53 [18] 53 [18] 52 [22] 
Cardiac Index, L/min per m² 2 [1] 2 [1] 2 [1] 2 [1] 
Cardiac Output, L/min  4 [2] 4 [2] 4 [2] 4 [2] 
Pulmonary Vascular Resistance, Wood units 11 [8] 11 [8] 12 [8] 11 [7] 
Pulmonary capillary wedge pressure, mmHg  9 ± 3 9 ± 3 9 ± 3 9 ± 3 
Mixed venous oxygen saturation, % 64 ± 8 64 ± 8 64 ± 8 64 ± 8 
Six-minute walk distance, meters 310 [203] 310 [203] 312 [208] 318 [228] 
Pulmonary function tests     
FEV1, %predicted 84 ± 19       84 ± 19       85 ± 18 84 ± 17 
Transfer coefficient (KCO), %predicted  74 ± 24 73 ± 24 73 ± 24 70 ± 23 
 
Area-level Deprivation       
q1 (most deprived) 95 (32) 93 (33) 76 (31) 40 (30) 
q2 68 (23) 66 (23) 56 (23) 29 (21) 
q3 61 (21) 58 (20) 49 (20) 33 (24) 
q4 52 (18) 51 (18) 44 (18) 23 (17) 
q5  19 (6) 18 (6) 18 (7) 10 (7) 
Household Income       
q1 41 (14) 39 (14) 33 (14) 17 (13) 
q2 40 (13) 39 (14) 32 (13) 16 (12) 
q3 40 (13) 39 (14) 35 (14) 22 (16) 
q4 50 (17) 49 (17) 44 (18) 28 (21) 
q5 (most deprived) 28 (9) 26 (9) 23 (9) 10 (7) 
q6 missing category 102 (34) 94 (33) 76 (31) 42 (31) 
Education       
Primary and Low-Secondary  62 (21) 59 (21) 47 (19) 23 (17) 
Upper and Post-Secondary 124 (41) 122 (43) 102 (42) 49 (36) 
Tertiary 90 (30) 81 (28) 73 (30) 52 (39) 
Missing category 25 (8) 24 (8) 21 (9) 11 (8) 
Smoking at diagnosis, n (%)       
Current smoker 22 (7) 22 (8) 19 (8) 10 (7) 
Former smoker 92 (31) 86 (30) 74 (30) 39 (29) 
Never smoker 46 (15) 45 (16) 34 (14) 15 (11) 
Missing category 141 (47) 133 (47) 116 (48) 71 (53) 
Ethnicity       
White 271 (90) 259 (91) 219 (90) 119 (88) 
Asian 18 (6) 16 (6) 15 (6) 11 (8) 
Other *** 12 (4) 11 (4) 9 (4) 5 (4) 
     
Data are presented as mean±standard deviation, n(%) or median [interquartile range]. 
* The percentages may not add up to 100% due to rounding. 
** The presence of emphysema was based on baseline chest computed tomography at the time of diagnosis. 
ゅゅゅ TｴW I;デWｪﾗヴ┞ さOデｴWヴざ ｷﾐIﾉ┌SWゲぎ Bﾉ;Iﾆが Mｷ┝WS ;ﾐS PヴWaWヴ ﾐﾗデ デﾗ ;ﾐゲ┘Wヴ 
PAH: pulmonary arterial hypertension; WHO: World Health Organization; FEV1: Forced expiratory volume in one second.  
 
Figure S1. Maps for 2010 annual average (A) particulate matter with aerodynamic 
diameter ≤2.5たm3 (PM2.5) concentration and (B) nitrogen dioxide (NO2) concentration 
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Legend - PM2.5: particulate matter witｴ ;WヴﾗS┞ﾐ;ﾏｷI Sｷ;ﾏWデWヴ гヲくヵ´ﾏンが NO2: nitrogen dioxide 
 
Figure S2. Time series and Location of Automatic Urban and Rural Network data for (A) Particulate Matter ≤2.5たm3 (PM2.5) and (B) 
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Figure S5. Linear Regression Estimating the Associations between Pulmonary 
Haemodynamics and Traffic Air Pollution for the crude and primary analysis models. 
 
Primary adjusted model: The model was adjusted for age, sex, functional class, and centre. Complete 
dataset with no missing data for the haemodynamics and the variables we adjusted for (N=243). 
 
Both exposure and haemodynamic outcomes were log-transformed. Therefore, the relative changes 
represent percentage change in the haemodynamics for a 60% increase in the traffic exposure 
indicators. A 60% increase in the geometric mean of traffic exposure indicators approximates to 
200m increases for distance to road, 0.6km increases for road length (500m buffer zone) and 1.5km 
increases for road length (1km buffer zone).  
 
N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP 
mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m², RAP: right 




Figure S6. Linear Regression Estimating the Associations between Pulmonary 
Haemodynamics and Particulate Matter ≤2.5たm3 (PM2.5) concentrations for the crude 
and primary analysis models. 
 
Primary adjusted model: The model was adjusted for age, sex, functional class, and centre. 
 
Log-transformed outcome variables (haemodynamics). The relative changes represent percentage 
change in haemodynamics per 3 g/m3 (interquartile range rounded to the nearest integer) increase 
in PM2.5 exposure. 
 
N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP 
mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m², RAP: right 
atrial pressure, mm Hg  
 
 
Figure S7. Linear Regression Estimating the Associations between Pulmonary 
Haemodynamics and Nitrogen Dioxide (NO2) concentrations for the crude and primary 
analysis models. 
Primary adjusted model: The model was adjusted for age, sex, functional class, and centre. 
 
Log-transformed outcome variables (haemodynamics). The relative changes represent percentage 
change in haemodynamics per 10 g/m3 (interquartile range rounded to the nearest integer) 
increase in NO2 exposure. 
 
N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP 
mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m², RAP: right 





Figure S8. Multivariable Linear Regression Estimating the Associations between 
Pulmonary Haemodynamics and Nitrogen Dioxide (NO2) concentrations, for the 
further-adjusted analysis models.  
 
Further-adjusted model: The model was adjusted for age, sex, functional class, smoking status at 
diagnosis, season, deprivation, income, education, body mass index, prevalent/incident cases, 
presence of BMPR2 gene mutation and centre. 
 
Log-transformed outcome variables (haemodynamics). The relative changes represent percentage 
change in haemodynamics per 10 g/m3 (interquartile range rounded to the nearest integer) 
increase in NO2 exposure. 
 
N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP 
mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m², RAP: right 
atrial pressure, mm Hg, BMPR2: bone morphogenetic protein receptor type II. 
